Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | CCR6 | P51684 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL569156 | 0.79 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2POLBDPP4LMNA | |
| SCHEMBL13786 | 0.79 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2POLBDPP4LMNA | |
| SCHEMBL88004 | 0.77 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2POLBDPP4LMNA | |
| SCHEMBL88005 | 0.77 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2POLBDPP4LMNA | |
| SCHEMBL2362353 | 0.76 | ZDHHC20 (0.46) | ALDH1A1HPGD | |
| SCHEMBL692534 | 0.74 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2POLBDPP4LMNA | |
| SCHEMBL173228 | 0.74 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2POLBDPP4LMNA | |
| SCHEMBL8845450 | 0.74 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2POLBDPP4LMNA | |
| SCHEMBL7156751 | 0.74 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2POLBDPP4LMNA | |
| SCHEMBL49389 | 0.74 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2POLBDPP4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099875-A1 | NEW ORTHO-FUNCTIONALIZED P-CHIRAL ARYLPHOSPHINES AND DERIVATIVES: THEIR PREPARATION AND USE IN ASYMMETRIC CATALYSIS | PHOSPHOENIX SARL (FR) | 2010-04-22 | — | — | US | claimed |
| US-5859190-A | SOLID PHASE SYNTHESIS TO FORM A PROTECTED DIPEPTIDE FOLLOWED BY REACTING WITH 1,1'-THIOCARBONYLDIIMIDAZOLE TO EFFECT RING FORMATION; EFFICIENCY; ANTICONVULSANT,-ARRHYTHMIC AND DIABETIC AGENTS; HERBICIDES AND FUNGICIDES | TREGA BIOSCIENCES, INC. (US) | 1999-01-12 | — | — | US | claimed |
| WO-1998033776-A1 | COMBINATORIAL LIBRARIES OF HYDANTOIN AND THIOHYDANTOIN DERIVATIVES, METHODS OF MAKING THE LIBRARIES AND COMPOUNDS THEREIN | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| US-5705499-A | VIRICIDES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1998-01-06 | — | — | US | claimed |
| US-5620974-A | ENZYME INHIBITOR, TREATS ACQUIRED IMMUNE DEFICIENCY SYNDROME(AIDS) | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1997-04-15 | — | — | US | claimed |
| EP-0767172-A1 | 8-Arylalkyl- and 8-arylheteroalkyl-5, 11-dihydro-6H-dipyrido-[3,2-b:2', 3'-e][1,4]diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1997-04-09 | — | — | EP | claimed |
| JP-5255248-A | — | — | None | — | — | JP | disclosed |
| US-8569267-B2 | Tetracyclic tetrahydrofuran derivatives containing cyclic amine side chain | JANSSEN PHARMACEUTICA, NV (BE) | 2013-10-29 | — | — | US | disclosed |
| US-20100099875-A1 | NEW ORTHO-FUNCTIONALIZED P-CHIRAL ARYLPHOSPHINES AND DERIVATIVES: THEIR PREPARATION AND USE IN ASYMMETRIC CATALYSIS | PHOSPHOENIX SARL (FR) | 2010-04-22 | — | — | US | disclosed |
| EP-1896456-B1 | NOVEL TETRACYCLIC TETRAHYDROFURAN DERIVATIVES CONTAINING A CYCLIC AMINE SIDE CHAIN | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-10 | — | — | EP | disclosed |
| US-7531655-B2 | Large conductance calcium-activated K channel opener | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20080262076-A1 | Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain | JANSSEN PHARMACEUTICA, NV (BE) | 2008-10-23 | — | — | US | disclosed |
| EP-1556376-B1 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-5859190-A | SOLID PHASE SYNTHESIS TO FORM A PROTECTED DIPEPTIDE FOLLOWED BY REACTING WITH 1,1'-THIOCARBONYLDIIMIDAZOLE TO EFFECT RING FORMATION; EFFICIENCY; ANTICONVULSANT,-ARRHYTHMIC AND DIABETIC AGENTS; HERBICIDES AND FUNGICIDES | TREGA BIOSCIENCES, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| WO-1998033776-A1 | COMBINATORIAL LIBRARIES OF HYDANTOIN AND THIOHYDANTOIN DERIVATIVES, METHODS OF MAKING THE LIBRARIES AND COMPOUNDS THEREIN | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| US-5705499-A | VIRICIDES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1998-01-06 | — | — | US | disclosed |
| US-5620974-A | ENZYME INHIBITOR, TREATS ACQUIRED IMMUNE DEFICIENCY SYNDROME(AIDS) | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0767172-A1 | 8-Arylalkyl- and 8-arylheteroalkyl-5, 11-dihydro-6H-dipyrido-[3,2-b:2', 3'-e][1,4]diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1997-04-09 | — | — | EP | disclosed |
| US-5366972-A | 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1994-11-22 | — | — | US | disclosed |
| JP-H05255248-A | NEW DERIVATIVE OF 1,2,5,6-TETRAHYDROPYRIDINE-3-CARBOXALDEHYDEOXIME, ITS MANUFACTURE AND USE AS DRUG | ROUSSEL UCLAF | 1993-10-05 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099875-A1 | NEW ORTHO-FUNCTIONALIZED P-CHIRAL ARYLPHOSPHINES AND DERIVATIVES: THEIR PREPARATION AND USE IN ASYMMETRIC CATALYSIS | PNP, NANP, PHOSPHO1 | ALDH1A1 834/4885SMN1; SMN2 3511/4885POLB 1626/4885 |
| US-20080262076-A1 | Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain | HTR2C, HTR2A, HTR5A | ALDH1A1 848/4885SMN1; SMN2 1902/4885POLB 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.